PeproMene Bio, Inc., IFLI, Institute for Follicular Lymphoma Innovation, PeproMene Bio, Inc.; IFLI

$PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma$

Press Releases

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

December 19, 2024

IRVINE, Calif. , Dec. 19, 2024 /PRNewswire/ -- PeproMene Bio, Inc. (PMB) has announced an $11M investment from the Institute for Follicular Lymphoma I...

Salamanca Press

Get in touch with The Salamanca Press

Submit Content

Advertise

Subscribe